Characterization of pulmonary function in Duchenne Muscular Dystrophy

Area of Science:

• Pulmonary Medicine
• Neuromuscular Disorders
• Clinical Trials

Background:

• Pulmonary function decline in Duchenne Muscular Dystrophy (DMD) significantly impacts morbidity and lifespan.
• Standard spirometry acceptability criteria (American Thoracic Society [ATS]) may be too stringent for neuromuscular disease patients.

Purpose of the Study:

• To assess the feasibility of obtaining acceptable spirometry in DMD patients.
• To evaluate lung function (Forced Vital Capacity [FVC], peak expiratory flow [PEF]) changes over time in DMD.
• To determine if ambulation status or glucocorticoid use affects lung function in DMD.

Main Methods:

• Prospective spirometry data (FVC, PEF) collected from 60 DMD patients (age 5-24).
• Data evaluated using modified ATS criteria suitable for neuromuscular disease.
• Analysis of lung function changes relative to age, ambulation, and steroid treatment.

Main Results:

• Acceptable spirometry obtained in 73% of subjects and 62% of all studies.
• Absolute FVC and PEF increased until age 10, stabilized until 18, then declined.
• Percent predicted FVC and PEF showed a consistent decline of ~5% per year (ages 5-24).
• No significant differences in FVC or PEF were observed based on ambulation status or steroid treatment.

Conclusions:

• Modified ATS criteria enable acceptable spirometry in DMD patients across a wide age range.
• Curated spirometry data provides a reliable method for tracking lung function changes in DMD.
• Ambulation status and steroid treatment did not appear to influence FVC or PEF trends in this cohort.